Karla Pray, NP
Adult Health · Gloucester, VANPI 1801153531
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Gilead at 56.2% of the total. Reporting peaked in 2022 at $5,039 and has fallen 72.7% since, to $1,376 in 2025. Among adult health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $72.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Eisai Inc.$322
- Ipsen Biopharmaceuticals, Inc$312
- AstraZeneca$278
- Exact Sciences$275
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$264
- plus $2K from 25 others
What the payments were for
- Consulting fees$2,04025%
- Travel & lodging$1,95124%
- Food & beverage$4,02349%
- Education$2083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 40 | $4,619 |
| Eisai Inc. | 8 | $322 |
| Ipsen Biopharmaceuticals, Inc | 3 | $312 |
| AstraZeneca | 4 | $278 |
| Exact Sciences | 3 | $275 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $264 |
| Intercept Pharmaceuticals, Inc. | 5 | $246 |
| Boston Scientific | 2 | $198 |
| Mirum Pharmaceuticals, Inc. | 2 | $188 |
| Exelixis Inc. | 2 | $144 |
| AbbVie | 7 | $143 |
| Johnson & Johnson | 2 | $134 |
| Genentech USA, Inc. | 1 | $131 |
| Intra-sana Laboratories | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $103 |
| Seagen Inc. | 1 | $99 |
| Novartis | 3 | $81 |
| Merck | 3 | $69 |
| Legend Biotech USA Inc. | 2 | $51 |
| Servier Pharmaceuticals LLC | 2 | $50 |
| Geron Corporation | 1 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Syndax Pharmaceuticals, Inc. | 1 | $31 |
| Taiho Oncology, Inc. | 1 | $26 |
| Sobi, Inc | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Sanofi | 1 | $23 |
| Pfizer | 1 | $18 |
| GSK | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$3,961
- IQIRVO$249
- Livmarli$165
- TheraSphere Y90 Glass Microspheres 10 GBq$145
- TECENTRIQ$131
- Reltone 200 Mg$125
- Reltone 400 Mg$125
- IMFINZI$123
- Cabometyx$123
- GIVLAARI$123
- OCALIVA$114
- XIFAXAN$111
How this compares
$8,222 in reported general payments places this provider in the 95th percentile of 368 adult health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 65 | $209,003 |
| Ursodiol | 69 | $19,559 |
| Mycophenolate Mofetil | 65 | $5,781 |
| Tacrolimus | 49 | $4,719 |
| Sirolimus | 17 | $2,506 |
| Lactulose | 24 | $1,475 |
| Cyproheptadine Hcl | 18 | $837 |
| Spironolactone | 33 | $792 |
| Furosemide | 51 | $305 |
| Omeprazole | 11 | $270 |
| Ondansetron Hcl | 12 | $224 |
| Gabapentin | 17 | $140 |
| Trazodone Hcl | 14 | $83 |
| Carvedilol | 14 | $73 |
| Pantoprazole Sodium | 19 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $264 | $209,00365 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 368 adult health providers in Virginia.
Other adult health in Gloucester
- Christine KesslerFort Belvoir$107K
- Denise BruenCharlottesville$45K
- Theresa Harrington StukusFairfax$40K
- Chelsea KoskovichFredericksburg$34K
- Brittany BrownLynchburg$14K
- Colleen DieringVirginia Beach$13K
- Veronica HughesRichmond$12K
- Nicole SellersNorfolk$12K
- Amy WenzelMechanicsville$11K
- Robert GrossmanDanville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.